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Cyclin D1 (CCND1) regulates cellular decision between
proliferation and growth arrest. Despite the functional
relevance of the CCND1 A870G single nucleotide poly-
morphism (SNP) published results on its association with
colorectal cancer (CRC) were inconsistent. We examined
the association between this CCND1 genotype and CRC
in the Singapore Chinese Health Study, a prospective
investigation of diet and cancer in 63 000 Chinese men and
women. We explored the hypothesis that inconsistency
regarding the CCND1/CRC association may be
attributable to the modifying effect of additional CRC
risk factors. Since GSTM1/GSTT1 genotype and dietary
isothiocyanate (ITC) intake had previously been identified
as CRC risk factors in this cohort, we now explored if they
influenced the CCND1/CRC association. In a nested case–
control study within the Singapore Cohort, genomic DNA
collected from 300 incident CRC cases and 1169 controls
was examined for CCND1, GSTM1, GSTT1 and GSTP1
polymorphisms. Unconditional logistic regression was
used to assess genotype effects on cancer risk. No main
effect of CCND1 was observed, yet the CCND1 effect
was influenced by ITC intake and GST genotypes. The
presence of at least one CCND1 A-allele was associated
with increased risk among low dietary ITC consumers
(intake below median value for the cohort) with a high-
activity GST profile (2 of the 3 GST genotypes classified
non-null or high-activity) [odds ratio (OR) ¼ 2.05; 95%
confidence interval (CI), 1.10–3.82]. In contrast, the
presence of at least one A-allele was associated with a
decreased risk among all remaining subjects (OR ¼ 0.56;
0.36–0.86) (P for interaction ¼ 0.01). Recent studies
indicate that ITCs inhibit cell proliferation and cause
apoptosis through pro-oxidant properties. The results of
our current study on CRC and those of our previous
breast cancer study are compatible with the notion of
oxidative stress in target cells as important determinant of
direction and magnitude of the CCND1 effect.
Introduction
Cancer is viewed in part as a cell-cycle disease (1). The
cyclin D1 protein, which is encoded by the CCND1 gene
located on chromosome 11q13, is therefore an important
candidate gene in tumorigenesis and cancer progression. As a
key cell-cycle regulatory protein modulating the restriction
point early in the G1 phase, cyclin D1 is a central determinant
in the cellular decision between survival, proliferation and
death (2–5).
For the cyclin D1 locus over 100 single nucleotide
polymorphisms (SNPs), but no common missense SNP have
been identified so far (6). The common A870G SNP remains
the most frequently investigated and the only functionally
characterized polymorphism. It modulates alternate splicing
of CCND1. Both alleles lead to the expression of two
different transcripts, but at different proportions. The A-allele
as the major source of transcript form b may lead to a protein
with a longer half-life, because it lacks a PEST sequence
postulated to target for rapid degradation (7–10). Additional
polymorphisms in CCND1 or trans-acting elements may
further modulate the splicing event (6).
Knudsen and colleagues (6) have recently reviewed the
epidemiological evidence regarding the association between
the CCND1 A870G SNP and cancers at different sites. While
the majority of studies linked the A-allele, especially in the
state of A/A genotype to increased cancer risk and poor
prognosis, some studies have also implicated the G-allele as
risk allele or did not find a risk association at all. Published
results on the associations between the CCND1 SNP and
colorectal cancer (CRC) are also mixed (reviewed in refs
6,10,12–19). The A/A or A/G genotype was associated with
early disease onset in sporadic and hereditary cancer (15,16).
Studies have reported either G/G (14) or A/A and A/G
genotype (12,17,19,20) to be risk genotypes for CRC or
adenomas. McKay et al. (18) found no association between
the A870G SNP and CRC. Previous studies mostly lacked the
inclusion of potential genetic/environmental effect modifiers
of the CCND1/cancer association.
In the Singapore Chinese Health Study, a prospective
investigation of diet and cancer in 63 000 Chinese men and
women of Singapore, we examined the potential association
between CCND1 genotype and CRC risk. In addition, we
explored the hypothesis, that the inconsistency in the main
effect of CCND1 genotype on CRC may partly be
attributable to the modifying effects of certain CRC risk
factors on this gene–risk association. Earlier, we had reported
an inverse association between dietary isothiocyanate (ITC)
and CRC, especially among subjects possessing the GSTM1/
GSTT1 null–null genotypes in the Singapore Chinese Health
Study (21). Experimental data have shown ITC, the primary
source of which is through dietary intake of cruciferous
vegetables, to be an inhibitory agent in carcinogen induced
colon carcinogenesis in animals (22,23). As an additional
Abbreviations: CCND1, cyclin D1 gene; CRC, colorectal cancer; GST,
glutathione-S-transferase; ITC, isothiocyanate; SNP, single nucleotide
polymorphism.
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exploratory analysis, we therefore investigated whether
this previously identified CRC risk pattern consisting of
dietary ITC and glutathione-S-transferase (GST) genotypes
exerts any influence on the CCND1 SNP-cancer risk
association.
Materials and methods
Study population
The subjects were participants of the Singapore Chinese Health Study,
a population-based, prospective investigation of diet and cancer risk (24).
Briefly, between April 1993 and December 1998, we recruited 63 257
Chinese men and women from two major dialect groups in Singapore
(Hokkien and Cantonese). The subjects were between the ages of 45 and
74 years and resided in government housing estates; at that time 86% of
Singapore’s population lived in such facilities. At recruitment, a face-to-face
interview was conducted by a trained interviewer, using a structured
questionnaire to elicit information on demographics, lifetime use of tobacco,
physical activity, menstrual and reproductive history, medical history and
family history of cancer. The questionnaire included a dietary component
assessing usual intake pattern (including frequency and portion size) during
the previous 12 months on 165 food and beverage items (24). The vegetable
section included nine cruciferous vegetables commonly consumed by Chinese
in Singapore (1). Average daily intake of roughly 100 nutrient and non-
nutrient compounds, including dietary ITC, was computed for each study
subject via linkage to the Singapore Food Composition Table. This semi-
quantitative food frequency questionnaire was subsequently validated against
a series of 24 h diet recalls (24). Average daily intake of ITC was expressed
as mmol/1000 kcal in all analysis to adjust for total energy intake.
Between April 1994 and July 1999, we collected blood and urine
specimens from a random 3% sample (n ¼ 1898) of study enrolees (n ¼
63 257). If the subject refused to donate blood, he/she was asked to donate
buccal cells collected through the use of a modified ‘mouthwash’ protocol
based on published methods (25). We collected blood (n ¼ 908) or buccal
cell (n ¼ 286) samples from 678 female and 516 male subjects during April
1994–July 1999. The participation rate in the biospecimen subcohort of the
study was 63%. Of these subjects, 13 developed CRC by April 30, 2002, the
remaining 1181 subjects constituted the reference group for the present
study. Demographic characteristics (sex, age at recruitment, dialect group,
level of education) of the control subjects who donated blood or buccal cells
were comparable to the whole cohort participants.
Case ascertainment
We identified incident CRCs through the population-based Singapore Cancer
Registry (26). As of April 30, 2002, 592 incident CRCs (ICDO C18–C20)
had developed among cohort subjects. All incident cases of CRC were
contacted as soon as they were identified by cohort staff for the donation of
biospecimens. However, due to refusal or early death, biospecimen collection
was successfully obtained only from 53% of all the cases. Thus, blood (n ¼
228) or buccal (n ¼ 84) specimens were available from 312 of 592 cases
of CRC. We manually reviewed the pathology report of each case to verify
his/her histopathological diagnosis of CRC. Compared with those who had
no formal education, a higher proportion of subjects with primary school or
higher education donated biospecimens (56 versus 46%). More male (56%)
than female (49%) cases and more Cantonese (57%) than Hokkien (49%)
cases donated biospecimens. Otherwise, the average age at diagnosis of
cancer was comparable between cases with and without biospecimens (65.4
versus 66.1 years).
Of the 312 cases with DNA specimens, we excluded 8 cases: carcinoma
in situ (1), carcinoid (11) and unknown histologic type (1). So the
present study included 304 cases of histologically confirmed CRC. The
CCND1 genotypes were non-informative on 12 controls and 4 cases.
Therefore, the present analysis included 1169 participants without and
300 subjects with CRC. A total of 151 CRC patients with stage 1 or stage
2 disease were classified as localized while 139 patients with stage 3 or
stage 4 disease were classified as advanced cancer. Ten cases had unknown
stage due to insufficient information. There were 173 colon cancer cases
(ICD codes C180–C189) and 127 rectum cancer cases (ICD code C199
and C209).
The study protocol was approved by the Institutional Review Boards of
the University of Minnesota, the National University of Singapore and the
University of Southern California. All participants gave written, informed
consents at the time of recruitment and at the time of biospecimen collection,
respectively.
Genotyping methods
DNA was purified from buffy coats of peripheral blood and buccal cell
samples using a QIAamp 96 DNA Blood Kit (Qiagen, Valencia, CA).
Genotyping for CCND1, GSTM1, GSTT1 and GSTP1 was performed using
the fluorogenic 5’-nuclease assay (TaqMan Assay) (27).
The TaqMan assays were performed using a TaqMan PCR Core Reagent
kit (Applied Biosystems Inc, Foster City, CA) according to manufacturer’s
instructions.
The CCND1 polymorphism (A/G) was described previously (28). The
oligonucleotide primers for amplification of the polymorphic region of
CCND1 were GC091for (50-CCCCAACAACTTCCTGTCCTACTA-30) and
GC091rev (50-AGGCTGCCTGGGACATCA-30). In addition, the fluorogenic
oligonucleotide probes (TaqMan MGB Probes; ABI) used to detect each of
the alleles were GC091F (50-CCTCACTTACCGGGTCA-30) labelled with 6-
FAM to detect the G allele and GC091V (50- CCTCACTTACTGGGTCA-30)
labelled with VIC to detect the A allele. PCR amplification using 10ng of
genomic DNA was performed in a thermal cycler (MWG Biotech, High
Point, NC) with an initial step of 95C for 10 min followed by 50 cycles of
95C for 25 s and 62C for 1 min. The fluorescence profile of each well was
measured in an ABI 7900HT Sequence Detection System and the results
analyzed with Sequence Detection Software (ABI). Experimental samples
were compared with 12 controls to identify the three genotypes at each locus
(A/A, A/G and G/G). Any samples that were outside the parameters defined
by the controls were identified as non-informative and were retested.
The oligonucleotide primers for amplification of the polymorphic region
of GSTP1 were GC070for (50-CCTGGTGGACATGGTGAATG-30) and
GC070rev (50-TGCTCACACCATAGTTGGTGTAGATGA-30). In addition,
the fluorogenic MGB oligonucleotide probes used to detect each of the
alleles were GC070F (50-TGCAAATACGTCTCCCT-30) labelled with 6-
FAM and GC070V (50-TGCAAATACATCTCCCT-30) labelled with VIC
(Applied Biosystems). PCR amplification consisted in the same procedure
described above for CCND1.
Genotyping of the GSTT1 and GSTM1 loci using the TaqMan assay
consisted of separate assays for GSTT1, GSTM1 and the albumin control
gene. The oligonucleotide primers for amplification of the GSTT1, GSTM1
and albumin genes were GC003for (50-GTGCAAACACCTCCTGGAGAT-30)
and GC003rev (50-AGTCCTTGGCCTTCAGAATGA-30), GC004 for
(50-CTTGGAGGAACTCCCTGAAAAG-30) and GC004 rev (50-TGGAACC-
TCCATAACACGTGA-30), GC005 for (50-CGATTTTCTTTTTAGGGCAG-
TAGC-30) and GC005 rev (50-TGGAAACTTCTGCAAACTCAGC-30),
respectively. Fluorescent oligonucleotide probes, for detection of PCR
reaction products, were synthesized to contain the dye 6-FAM (BioSearch
Technologies, Novato, CA). The probes for the GSTT1, GSTM1 and albumin
genes were GC003FAM (50-ATGCTGCCCATCCCTGCCC-30), GC004FAM
(50-AAGCGGCCATGGTTTGCAGG-30) and GC005FAM (50-CGCCTGA-
GCCAGAGATTTCCCA-30), respectively. PCR amplification using 10 ng
of genomic DNA was performed in an ABI 7900HT Sequence Detection
System (Applied Biosystem) with an initial step of 95C for 10 min followed
by 50 cycles of 95C for 25 s and 62C for 1 min. The fluorescence profile
of each well was measured in real-time during the PCR amplification and the
results analyzed with Sequence Detection Software (ABI). Any sample with
a fluorescence signal that crossed a threshold of 0.2 DRn before cycle 40 was
considered positive for the loci analyzed. Samples negative for both GSTT1
and GSTM1 must be positive for albumin to be called; otherwise, the sample
was designated non-informative and retested. All analyses were carried out
blind to case or control status.
Statistical analysis
Although we sampled our controls randomly from the whole cohort, our
study is more case–control than case–cohort in design since time of follow-
up was relatively short (mean 4.1 years; ranging from 6 days to 8.8 years)
and comparable between cases and the subcohort, with only 13 subjects in
the latter group developing CRC during the observation period. Therefore,
we analysed our data using both case–cohort (Epicure software PEANUTS
procedure, Hirosoft, Seattle, WA) and case–control methods (29) and the
two sets of results are similar. Figures presented in this report are derived
from our case–control analyses. Specifically, we used unconditional logistic
regression methods to examine the effect of the A870G polymorphism
of CCND1 on CRC risk, with and without stratification by levels of dietary
ITC and GST genotypes, separately and in combination. Indicator variables
for the genotypes of CCND1 (GG, GA, AA; GA/AA) were created using the
GG-genotype as the reference category. The median value of dietary ITC
(5.16 mmol/1000 kcal) among all cohort members was used to separate
individuals into the high (above median) versus low (below median) intake
categories. GSTM1 and GSTT1 null genotypes were subjects homozygous for
the respective gene deletions. The GSTP1 polymorphism has been shown to
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influence GSTP1 activitiy, with the direction of the effect being substrate
dependent (30) Based on prior empirical findings with cancer risk (31)
GSTP1 AA genotype was considered the putative high-activity genotype
compared with the AB/BB genotypes in this current study. The strength of
the gene–cancer associations was measured by odds ratio (OR) and its
95% confidence interval (CI). The following covariates were included in
all gene–disease regression models: gender, age at recruitment (years), year
of recruitment (1993–1998), dialect group (Hokkien, Cantonese), level of
education (no formal education, primary school only, secondary school or
higher), body mass index (BMI) (<20, 20 to <24, 24 to <28, or 28 kg/m2),
smoking status at baseline (never, former, current), alcohol consumption at
baseline (none, <7, 7 drinks/week) and family history of CRC (yes, no). In
all analyses, we formally tested for the potential difference in findings
between men and women. Since no gender effects were found, all results are
shown for both sexes combined. The polytomous logistic regression method
was used to examine associations of interest by subsite (colon, rectum) and
by stage of disease (localized, advanced) (32). The linear trend tests for
exposure–disease associations (Table I) were based on ordinal values of the
specific exposures.
Statistical analysis was carried out using the SAS version 9.1 (SAS
Institute, Cary, NC). All P-values are two-sided and P < 0.05 were
considered statistically significant.
Table I. Distribution of selected variables in CRC patients and controls, Singapore Chinese Health Study
Variables Controls Cases OR (95% CI)
N (%) N (%)
Gender
Male 504 (43) 172 (57) —
Female 665 (57) 128 (43)
Dialect group
Cantonese 566 (48) 135 (45) —
Hokkien 603 (52) 165 (55)
Education
No formal education 314 (27) 91 (30) —
Primary school 504 (43) 149 (50)
Secondary school or higher 351 (30) 60 (20)
BMI (kg/m2)
<20 186 (16) 45 (15) 1.00
20–<24 653 (56) 144 (48) 0.78 (0.53–1.15)
24–<28 266 (23) 91 (30) 1.35 (0.88–2.07)
28 64 (5) 20 (7) 1.40 (0.75–2.64)
P-trend 0.01
Hours per week of moderate activitiesa
<0.5 877 (75) 224 (74) 1.00
0.5–3 186 (16) 44 (15) 0.78 (0.53–1.14)
4+ 106 (9) 32 (11) 0.82 (0.52–1.28)
P-trend 0.21
Weekly vigorous work/sportsb
No 1024 (88) 270 (90) 1.00
Yes 145 (12) 30 (10) 1.14 (0.73–1.79)
Cigarette smoking status at baseline
Never 848 (73) 179 (59) 1.00
Ex 129 (11) 50 (17) 1.04 (0.68–1.59)
Current 192 (16) 71 (24) 1.22 (0.85–1.76)
Alcohol drinking at baseline (number of drinks/week)
0 957 (82) 233 (78) 1.00
<7 164 (14) 42 (14) 1.00 (0.67–1.50)
7+ 48 (4) 25 (8) 2.07 (1.20–3.59)
P-trend 0.04
Family history of CRC
No 1141 (98) 287 (96) 1.00
Yes 28 (2) 13 (4) 2.36 (1.15–4.84)
Dietary ITC
Lowc 587 (50) 176 (59) 1.00
High 582 (50) 124 (41) 0.82 (0.63–1.08)
GSTM1 genotype
Positive 643 (55) 168 (56) 1.00
Null–null 525 (45) 132 (44) 0.89 (0.68–1.16)
GSTT1 genotype
Positive 693 (59) 200 (67) 1.00
Null–null 475 (41) 100 (33) 0.71 (0.54–0.94)
GSTP1 genotype
AAd 770 (66) 211 (70) 1.00
AB 346 (30) 80 (27) 0.91 (0.67–1.23)
BB 53 (4) 9 (3) 0.68 (0.32–1.44)
ORs were adjusted for gender, dialect group (Cantonese, Hokkien), age at recruitment (years), year of recruitment (1993–1998) and education (no formal
education, primary school, secondary school or higher).
aModerate activities included brisk walking, bowling, bicycling on level ground, tai chi or chi kung.
bVigorous work/strenuous sports included moving heavy furniture, loading or unloading trucks, shovelling or equivalent manual labor, jogging, bicycling on
hills, tennis, squash, swimming laps or aerobics.
cLow ¼ below median value (5.16 mmol/1000 kcal) for the entire cohort.
dAA ¼ putative high-activity genotype.
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Results
The characteristics of the study population are summarized
in Table II. Factors positively associated with risk were high
BMI, cigarette smoking and alcohol intake. Dietary ITC was
inversely associated with risk (P for trend with ITC intake as
continuous variable ¼ 0.19). Mean age at cancer diagnosis
among the cases was 65.3 years [standard deviation (SD) ¼
7.7]. Mean age at recruitment was 61.2 years (SD ¼ 7.5) for
cases and 56.5 years (SD ¼ 8.1) for controls.
The distribution of CCND1 genotypes by case–control
status and stage of disease is summarized in Table II. The
frequency of the A-allele in control subjects was 59%.
The genotype distribution among controls was in Hardy–
Weinberg equilibrium (P ¼ 0.27). Overall, there was
no association between CCND1 genotype and CRC. This
genotype–cancer association did not differ by stage of
disease or by subsite (colon versus rectum; data not shown).
Table II shows the associations between CCND1 genotype
and CRC risk separately for subjects with low versus high
dietary ITC. Among subjects with high dietary ITC intake,
the presence of one or two A-alleles was associated with a
decreased risk of CRC (OR ¼ 0.57; 95% CI ¼ 0.33–0.97 and
OR ¼ 0.55; 95% CI ¼ 0.31–0.96, respectively). The effect
modification of the CCND1/CRC association by ITC intake
level was not materially altered by shifting the ITC high
versus low cutoff point (top quartile versus rest; lowest
quartile versus rest; tertiles). The P-value for an interaction
term between CCND1 genotype (GG versus non-GG) and
ITC intake as a continuous variable was 0.02.
Table II also presents the effects of CCND1 genotype on
CRC risk according to subjects’ GST genotypes. Among
subjects possessing the GST null (low- activity) genotypes,
there was a consistent, inverse relationship between risk for
CRC and one or two copies of the CCND1 A-allele relative
to the GG-genotype. The OR was 0.60 (95% CI ¼ 0.24–1.48)
among subjects with the homozygous GSTM1 and T1 null–
null genotypes while the comparable figures for those
with either the GSTM1 or T1 positive genotypes was 0.96
(95% CI ¼ 0.66–1.40). The OR was 0.62 (95% CI ¼ 0.34–
1.13) among subjects with the GSTP1 AB/BB (putative low-
activity) genotypes while the comparable figures for those
with the GSTP1 AA genotype was 1.08 (95% CI, 0.70–1.66).
When subjects were classified according to their combined
GSTM1/GSTT1/GSTP1 genotypes, the OR was 0.53 (95%
CI ¼ 0.28–0.98) among those with at most one of the three
genotypes being classified as positive or high-activity
(referred to as the low-activity GST profile). The comparable
figures for subjects with at least two positive/high-activity
genotypes out of the possible three (the high-activity GST
profile) were 1.14 (95% CI ¼ 0.75–1.74). None of the results
presented in Table II were materially altered by excluding
cases with <2 years of follow-up time from the analysis.
Table III presents the CCND1 genotype/CRC risk associa-
tions according to subjects’ combined status on dietary ITC
and GST genotypes. The presence of at least one CCND1
A-allele was associated with a significant increased risk for
CRC among low consumers of dietary ITC who possessed a
high-activity GST profile (OR ¼ 2.05; 95% CI ¼ 1.10–3.82).
In contrast, the presence of at least one A-allele was
associated with a significant decreased risk for CRC among
all remaining subjects (i.e. those with either high dietary
ITC levels or a low-activity GST profile) (OR ¼ 0.56;
95% CI ¼ 0.36–0.86). These two ORs were statistically
significantly different from each other (P for interaction ¼
0.01). Again, the effect modification of the CCND1/CRC
association by dietary ITC and GST genotypes was not
materially altered by shifting the ITC high versus low cutoff
Table II. Cyclin D1 (CCND1) G870A genotype in relation to CRC risk, stratified by stage of disease, ITC intake and GST genotypes, the Singapore Chinese
Health Study
Variables CCND1 genotype
GG GA AA GA/AA
Ca/Co OR Ca/Co OR (95% CI) Ca/Co OR (95% CI) Ca/Co OR (95% CI)
Total subjects 56/207 1.00 132/548 0.86 (0.59–1.25) 112/414 0.95 (0.65–1.39) 244/962 0.90 (0.64–1.27)
Localizeda 31/207 1.00 59/548 0.67 (0.41–1.09) 61/414 0.91 (0.56–1.49) 120/962 0.78 (0.50–1.21)
Advanced 23/207 1.00 69/548 1.13 (0.68–1.88) 47/414 0.99 (0.58–1.69) 116/962 1.07 (0.66–1.73)
Low ITCb 25/103 1.00 80/273 1.27 (0.75–2.16) 71/211 1.54 (0.90–2.65) 151/484 1.39 (0.84–2.28)
High ITC 31/104 1.00 52/275 0.57 (0.33–0.97) 41/203 0.55 (0.31–0.96) 93/478 0.56 (0.34–0.91)
GSTM1 positive (1) 35/131 1.00 66/293 0.80 (0.50–1.30) 67/219 1.12 (0.69–1.82) 133/512 0.94 (0.60–1.46)
GSTM1 Null-Null (0) 21/76 1.00 66/254 0.89 (0.49–1.62) 45/195 0.75 (0.40–1.39) 111/449 0.83 (0.47–1.46)
GSTT1 positive (1) 37/122 1.00 91/318 0.88 (0.56–1.40) 72/253 0.84 (0.52–1.36) 163/571 0.87 (0.56–1.33)
GSTT1 Null-Null (0) 19/85 1.00 41/229 0.83 (0.43–1.58) 40/161 1.21 (0.63–2.32) 81/390 0.98 (0.54–1.78)
GSTP1 AA (1) 35/134 1.00 96/351 1.09 (0.69–1.73) 80/285 1.06 (0.66–1.71) 176/636 1.08 (0.70–1.66)
GSTP1 AB/BB (0) 21/73 1.00 36/197 0.52 (0.27–1.00) 32/129 0.78 (0.40–1.52) 68/326 0.62 (0.34–1.13)
GSTM1 or T1 positive 47/172 1.00 112/438 0.91 (0.61–1.37) 96/336 1.01 (0.67–1.53) 208/774 0.96 (0.66–1.40)
GSTM1 and T1 null 9/35 1.00 20/109 0.60 (0.23–1.59) 16/78 0.60 (0.23–1.59) 36/187 0.60 (0.24–1.48)
Summed score of GSTM1/T1/P1
2,3c 36/143 1.00 96/340 1.11 (0.71–1.74) 81/262 1.19 (0.74–1.89) 177/602 1.14 (0.75–1.74)
0,1d 20/64 1.00 36/207 0.48 (0.24–0.95) 31/152 0.58 (0.29–1.17) 67/359 0.53 (0.28–0.98)
aLocalized disease was defined as stages 1 and 2. Advanced disease was defined as stages 3 and 4.
bBelow versus above median value for the entire cohort.
cAt least 2 of the 3 GST genotypes being classified as positive or high-activity (referred as the high-activity GST profile).
dAt most 1 of the 3 GST genotypes being classified as positive or high-activity (referred as the low-activity GST profile).
ORs were adjusted for gender, age at recruitment (years), year of recruitment (1993–1998), dialect group (Cantonese, Hokkien), education (no formal
education, primary school, secondary or higher), BMI (<20, 20–<24, 24–<28, 28+ kg/m2), smoking status at baseline (never, former, current), alcohol
consumption at baseline (none, <7, 7+ drinks/week) and family history of CRC (no, yes).
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point (top quartile versus rest; lowest quartile versus rest;
tertiles).
Discussion
In the present study there was no main effect of CCND1
A870G on CRC risk, but our exploratory analysis found that
the CCND1 A870G effect is modified by the level of ITC
intake, GST genotype and their combination. The presence
of an A-allele conferred an increased risk for CRC among
subjects with low ITC intake and no GST deficiency. In
contrast among subjects with either high ITC intake or a
low-acitivity GST profile, the presence of an A-allele was
associated with a decrease in CRC risk.
Our current findings relating CCND1 genotype to CRC
risk and those of our previous study on breast cancer in this
same cohort (11) are suggestive of oxidative stress as the
biological underpinning for the observed effect modification
by GST genotypes, dietary n-3 and n-6 fats (breast cancer)
and dietary ITC (CRC). Our hypothesis is based on several
lines of evidence. First, cell-cycle checkpoint responses to
oxidative stress, a significant source of endogenous and
exogenous DNA damage, are well documented and include
up- and down-regulation of cyclin D1. Experimental data
demonstrate that reactive oxygen species (ROS) modulate the
G1 checkpoint and the direction of cyclin D1/Cdk4/6 activity
on the cell cycle (33). Partially through the regulation of
cyclin D1 expression, oxidants are important regulators of the
signalling events dictating decisions between cell survival,
proliferation or death (4,34,35). Second, novel evidence
points to the relevance of this pathway to colorectal tumori-
genesis. Malfunction of the Wnt signalling pathway with
abnormal stabilization of b-catenin is a key causative step in
CRC, and the effect may in part be attributed to an abnormal
regulation of the oxidative stress impact on the cell cycle
(36). b-catenin was identified as an important regulator
of cyclin D1 in colon carcinoma cells (37). In addition,
b-catenin was recently found to act as a cofactor for
the FOXO subfamily of winged helix transcription factors,
which induce cell-cycle arrest and quiescence in response to
oxidative stress (36). Third, experimental evidence docu-
ments a pro-oxidative effect of ITCs on the cell-cycle and on
CCND1 expression. The biological mechanisms underlying
the cancer-protective effect of ITC are still poorly understood
(38). Initially the anticancer effects of ITC were attributed
exclusively to modulation of carcinogen metabolism includ-
ing the induction of oxidant-scavenging GSTs. More recent
studies have indicated that ITCs can additionally inhibit
proliferation of cancer cells by causing cell-cycle arrest
and/or apoptosis (35,38,39–41). The growth inhibiting impact
of ITCs on target cells is attributed to a pro-oxidant action of
these compounds on cell-cycle progression/arrest and on
cyclin D1 expression (35,39,42–46). For example, incubation
of pancreatic cancer cell lines with N-acetyl-L-cysteine was
associated with resistance to apoptosis induced by the ITC
compound sulforaphane (47). In addition, sulforaphane was
recently found to inhibit the serum-stimulated growth of the
human colon cancer cell line HT-29 by blocking the cell
cycle at G1 phase via activation of MAPKs pathways,
including ERK, JNK and p38. This effect was abrogated
when the cell lines were exposed to both sulforaphane and an
antioxidant simultaneously (38).
Our results are consistent with the laboratory data
described above, and suggest that the A-allele protects
against CRC among subjects with an enhanced state of
oxidative stress (i.e. high ITC consumption or low-activity
GST profile). These results are compatible with our previous
report on the CCND1 SNP association with breast cancer, in
which the protective effect of the CCND1 A-allele on breast
cancer risk was mainly confined to women possessing a
genetic/dietary profile that is associated with an enhanced
state of oxidative stress (11). Interestingly, we now found
that the A-allele increased CRC risk among subjects with a
decreased state of oxidative stress (i.e. low ITC consumption
and high-activity GST profile). This risk increasing effect of
the A-allele under conditions of low oxidative stress was not
statistically significant in our earlier breast cancer report (11).
Previously, we demonstrated a protective effect of ITC intake
on CRC (21) and colorectal adenomas (48) that was restricted
to the GSTM1 and GSTT1 null genotypes. This observation
was attributed to the effects of the GSTs on ITC excretion. In
light of our present results, we may now also hypothesize
that subjects with low intake level of ITC and functional
GST enzymes are left with low levels of pro-oxidative acting
ITC at a cellular level. An oxidant-level dependent direction
Table III. Cyclin D1 (CCND1) G870A genotype in relation to CRC risk, stratified by GST genotypes and ITC intake in combination, the Singapore Chinese
Health Study
ITCa Summed score of
GST M1/T1/P1
CCND1 genotype
GG GA AA GA/AA
Ca/Co OR Ca/Co OR (95% CI) Ca/Co OR (95% CI) Ca/Co OR (95% CI)
Low 2,3b 15/77 1.00 61/172 1.96 (1.02–3.78) 53/142 2.17 (1.11–4.22) 114/314 2.05 (1.10–3.82)
Low 0,1c 10/26 1.00 19/101 0.46 (0.17–1.25) 18/69 0.75 (0.27–2.08) 37/170 0.57 (0.23–1.43)
High 2,3b 21/66 1.00 35/168 0.60 (0.31–1.15) 28/120 0.60 (0.30–1.20) 63/288 0.60 (0.33–1.10)
High 0,1c 10/38 1.00 17/106 0.55 (0.20–1.48) 13/83 0.49 (0.18–1.35) 30/189 0.52 (0.21–1.29)
Low 0,1 or High 0,1,2,3 41/130 1.00 71/135 0.54 (0.34–0.85) 59/272 0.59 (0.36–0.96) 130/647 0.56 (0.36–0.86)
aBelow versus above median value for the entire cohort.
bAt least 2 of the 3 GST genotypes being classified as positive or high-activity (referred as the high-activity GST profile).
cAt most 1 of the 3 GST genotypes being classified as positive or high-activity (referred as the low-activity GST profile).
ORs were adjusted for gender, age at recruitment (years), year of recruitment (1993–1998), dialect group (Cantonese, Hokkien), education (no formal
education, primary school, secondary or higher), BMI (<20, 20–<24, 24–<28, 28+ kg/m2), smoking status at baseline (never, former, current), alcohol
consumption at baseline (none, <7, 7+ drinks/week) and family history of CRC (no, yes).
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of the A-allele effect agrees well with the experimentally
documented context-dependent dual role of cyclin D1, which
also has been documented for other cell-cycle regulators
(5,49–55). Functional data for the CCND1 A870G SNP
suggest that carriers of one or two A-alleles produce protein
with a longer half-life (7,28,56–57). Our findings suggest that
this gene variant increases protein activity on both cellular
proliferation and growth inhibition, with the direction of the
effect determined in part by the level of oxidative stress in
target cells.
The present study is the first to investigate the association
between the A870G CCND1 SNP and CRC risk stratified by
GST genotypes and ITC consumption. Results on the main
effect of CCND1 genotype on risk, prognosis and age at
onset of familial and non-familial CRC have been inconsis-
tent (6,10,13,15–19). The Hawaii/Los Angeles Multiethnic
Cohort Study found the A-allele to be more prominent
in CRCs diagnosed at a regional or distant stage (12).
The associations were statistically significant in White
and Hawaiian, but not in Japanese participants. In contrast,
a case–control study in Singapore found the GG-genotype to
relate to increasing risk (14). In the Hawaii/Los Angeles
Multiethnic Cohort Study, mean daily intake of cruciferious
vegetables among Japanese-American, White and Native
Hawaiian participants were 44.9, 40.4 and 46.4 g/day,
respectively, in men and 49.2, 43.2 and 51.4 g/day,
respectively, in women (58). In the Singapore Chinese
Health Study, average daily intake of cruciferous vegetables
among cohort participants was 41 g/day (59). Therefore,
there is no evidence that the possibly modifying effect of
dietary ITC on the CCND1 genotype–CRC association is
behind the discrepant results noted in the US versus
Singapore Chinese. Additional external as well as internal
factors potentially underlying the disparate effects of the
CCND1 A870G SNP in different populations must be
investigated. Smoking, obesity, family history of cancer and
post-menopausal hormone use in women have been
suggested as potential effect modifiers of CCND1 A/G870
SNP/cancer association (20,60–61). Furthermore, modifiers
including additional polymorphisms in the CCND1 gene or
trans-acting factors which influence transcript ‘a’ versus
‘b’ splicing of the CCND1 gene independent of the A870G
SNP must be identified (6). The latter aspect is of special
relevance given that Bala and Ptelomaki (10) found CCND1
transcript ‘b’ production, but not the A870G SNP to be
associated with the prognosis of CRC.
This study has several strengths. Dietary assessment was
conducted using a validated, semi-quantitative food fre-
quency questionnaire. We had previously reported a highly
statistically significant correlation between daily intake of
cruciferous vegetables or daily ITC intake and urinary ITC
levels in study subjects (59). All exposure assessments
occurred prior to cancer diagnosis, and therefore, could be
presumed to be free of recall bias. In addition, the study
population is genetically homogeneous since they are full-
blooded descendents of natives from two contiguous prefec-
tures in southern China. There is a theoretical concern for
selection bias arising from the higher availability of blood
specimens among Cantonese versus Hokkien cases with
CRC and the higher levels of education among cases with
blood specimens versus those without blood specimens. We
examined if CCND1 genotype is related to dialect group or
education among CRC cases, and no associations were found
(P ¼ 0.68 for dialect group; and P ¼ 0.89 for education).
Given that dialect group and education are not confounders
of the hypothesized CCND1/CRC association in our study
population, the unequal distributions of these two factors
between cases with and without blood specimens should not
impact on the validity of our study findings.
A major limitation of our study is its low statistical power
for the assessment of gene–environment and gene–gene inter-
actions, due to the rather modest number of incident CRCs to
date within this cohort of Singapore Chinese subjects.
However, the consistency of the results across the two dif-
ferent types of cancer (breast and colorectum) in this
population-based cohort lends credence to the validity of
both sets of results (11). As this long-term, prospective
investigation continues to accrue incident cases of CRC, we
will have the opportunity to revisit this hypothesis with
sufficient statistical power, using a haplotype approach as
opposed to examining single polymorphisms one at a time,
and studying additional markers of oxidative stress.
The present study highlights the modifying effects of
genetic and environmental cofactors on the low penetrance
genotype in relation to a given disease risk. Thus, one
should be cautious in generalizing a given genotype–disease
association across populations with varying lifestyles, dietary
habits or genetic background. This may be especially relevant
for genes involved in tightly regulated processes such as cell
cycle and DNA repair. Our exploratory findings suggest
that the oxidant–antioxidant balance in cells may be an
important determinant of the direction of the cyclin D1
checkpoint function and thus of the CCND1 genotype effect
on carcinogenesis.
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